Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
- 1 October 1999
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 13 (14), 1863-1871
- https://doi.org/10.1097/00002030-199910010-00008
Abstract
To determine whether baseline drug resistance assays could help to predict treatment failure with the protease inhibitor combination ritonavir-saquinavir. Baseline HIV-1 drug resistance was determined for 76 consecutive patients who started treatment with the dual protease inhibitor combination ritonavir-saquinavir between September 1996 and June 1997 either alone or in combination with other antiviral agents. Resistance to 10 different antiviral agents was assessed by both phenotype (Virco Antivirogram) and genotype (Vircogen). Resistance inferred from viral genotype was similar to measured phenotypic resistance for both ritonavir and saquinavir (P0.8 log10 for those with sensitive virus. Patients resistant to both drugs never achieved plasma viral loads <100000 copies/ml. As little as fourfold increases in baseline resistance appeared to be sufficient to compromise even dual protease inhibitor therapy. Baseline resistance to ritonavir or saquinavir or both was associated with a poor antiviral response. Our data suggest that the measurement of drug resistance may assist in optimizing antiretroviral therapy in the clinic.Keywords
This publication has 12 references indexed in Scilit:
- HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapyAIDS, 1998
- Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failureAIDS, 1998
- Antiretroviral Drug Resistance Testing in Adults With HIV InfectionJAMA, 1998
- Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir*Clinical Pharmacology & Therapeutics, 1998
- The antiviral effect of ritonavir and saquinavir incombination amongst HIV-infected adultsAIDS, 1998
- Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisionsJournal of Antimicrobial Chemotherapy, 1997
- Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavirAIDS, 1997
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- In Vivo Resistance to a Human Immunodeficiency Virus Type 1 Proteinase Inhibitor: Mutations, Kinetics, and FrequenciesThe Journal of Infectious Diseases, 1996
- Interactions Between Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse TranscriptaseJournal of General Virology, 1994